CI vs VNDA: fair value comparison
The Cigna Group and Vanda Pharmaceuticals Inc. · Updated 2026-09-07
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, CI currently sits closer to the top of our discount ranking. VNDA carries the stronger quality grade.
| CI | VNDA | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $282.52 | $5.23 |
| 12-month range | $244.41–$289.26 | $4.47–$8.25 |
| Sector rank | #34 of 113 Healthcare | #36 of 113 Healthcare |
| Quality grade | F | D |
| Leverage | Moderate | Low |
| Margin trend | Contracting | — |
| Revenue growth | Strong | — |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Mixed |
| DCF cross-check | Undervalued | — |
| 52-week position | The top quarter | The bottom quarter |
Full single-stock breakdowns: CI fair value analysis · VNDA fair value analysis